Disease or Syndrome – Page 28

Terns to Stop Funding Metabolic Disease Trials Beyond 2025; Seeks Partners for Assets

3 months ago talkbio0Tagged agonists, Clinical Trials, Glucagon-Like Peptide 1, Metabolic Diseases, Myeloid Leukemia, Chronic, Oncology Focus, Partnering, Pipeline Strategy, TERN-601, TERN-701, Terns

Terns Pharmaceuticals; metabolic disease; clinical trials; pipeline strategy; partnering; oncology focus; TERN-601; TERN-701; GLP-1 agonists; CML

How Science Drives Better Business Decisions in Biopharma (2025 Update)

3 months ago talkbio0Tagged Artificial Intelligence, Biopharma, business strategy, data-driven decisions, decision science, digital twins, innovation, portfolio strategy, R&D

biopharma; decision science; AI; digital twins; R&D; portfolio strategy; data-driven decisions; innovation; business strategy

Pfizer’s Embattled Obesity Program Loses Another GLP-1 Drug Due to Data and Competition Issues

3 months ago talkbio0Tagged Agonist, Clinical Trials, competition, Danuglipron, Drug Development, Glucagon-Like Peptide 1, Injury of liver, lotiglipron, Obesity, PF-06954522, Pfizer

Pfizer; obesity; GLP-1 agonist; clinical trial; liver injury; danuglipron; lotiglipron; PF-06954522; obesity drug development; competition

BioMarin Drops Preclinical PKU Drug Once Seen as Potential Palynziq Successor

3 months ago talkbio0Tagged BioMarin, Drug Development, Immunogenicity (package insert), Palynziq, Phenylketonurias, R&D pipeline

BioMarin; PKU; Palynziq; BMN 390; drug development; R&D pipeline; immunogenicity

Imunon Halts COVID-19 Vaccine Program, Seeks Partner Due to Financial Struggles

3 months ago talkbio0Tagged Cash Crunch, COVID19 (disease), deprioritization, financial results, IMNN-101, Imunon, Partnership, Vaccines

Imunon; COVID-19 vaccine; IMNN-101; deprioritization; cash crunch; partnership; financial results

Scientists Protest FDA’s Rejection of Replimune’s Tumor Destroying Therapy

3 months ago talkbio0Tagged Clinical Trials, Drug Approval, Heterogeneity, IGYNTE, melanoma, Oncolytic Immunotherapy, Rejection, Replimune, RETINITIS PIGMENTOSA 1, scientist protest, United States Food and Drug Administration

Replimune; RP1; FDA rejection; oncolytic immunotherapy; melanoma; clinical trial; IGYNTE study; scientist protest; drug approval; patient heterogeneity

Praxis Seizure Drug Vormatrigine Shows Strong Efficacy in Phase 2 Trial

3 months ago talkbio0Tagged Clinical Research, Epilepsy, focal onset seizures, Praxis Precision Medicines, Radiant heater, Seizures, Sodium Channel Blockers, vormatrigine

Praxis Precision Medicines; vormatrigine; epilepsy; seizures; RADIANT study; focal onset seizures; Phase 2 trial; sodium channel blocker

Praxis touts ‘best-in-disease’ epilepsy data, but shares dip

3 months ago talkbio0Tagged anti-seizure medication, Clinical Research, Clinical Trials, Epilepsy, focal onset seizures, Market, Praxis Precision Medicines, Radiant heater, Seizures, vormatrigine

Praxis Precision Medicines; epilepsy; vormatrigine; RADIANT study; focal onset seizures; Phase 2 trial; seizure reduction; clinical trial; anti-seizure medication; stock market

Replimune Awaits FDA Direction After Complete Response Letter for Advanced Melanoma Therapy

3 months ago talkbio0Tagged Accelerated, Advanced Melanoma, Approved, Cancer Therapeutic Procedure, Complete, IGNYTE trial, nivolumab, Replimune, Response Letter, RETINITIS PIGMENTOSA 1, United States Food and Drug Administration, vusolimogene oderparepvec

Replimune; FDA; Complete Response Letter; RP1; vusolimogene oderparepvec; nivolumab; advanced melanoma; cancer treatment; IGNYTE trial; accelerated approval

Untangling Sarepta’s Gene Therapy Fallout and Trust Deficit

3 months ago talkbio0Tagged AAVrh74 vector, clinical holds, ELEVIDYS, gene therapy, Muscular Dystrophies, Limb-Girdle, Muscular Dystrophy, Duchenne, patient deaths, Regulatory Action, United States Food and Drug Administration

Sarepta Therapeutics; gene therapy; Elevidys; Duchenne muscular dystrophy; limb-girdle muscular dystrophy; patient deaths; FDA; AAVrh74 vector; regulatory action; clinical holds; transparency